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Abstract
Background: We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal
antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet
RoAD (SR) and Marguerite RoAD (MR) phase 3 trials. Several lines of evidence suggested that higher doses may be
necessary to achieve clinical efficacy. We therefore designed a positron emission tomography (PET) substudy to
evaluate the effect of gantenerumab uptitrated to 1200 mg every 4 weeks on amyloid-β plaques as measured using
florbetapir PET in patients with prodromal to moderate Alzheimer’s disease (AD).
Methods: A subset of patients enrolled in the SR and MR studies who subsequently entered the open-label
extensions (OLEs) were included in this substudy. Patients were aged 50 to 90 years with a clinical diagnosis of
probable prodromal to moderate AD and were included based on a visual read of the original screening scan in
the double-blind phase. Patients were assigned to 1 of 5 titration schedules (ranging from 2 to 10 months) with a
target gantenerumab dose of 1200 mg every 4 weeks. The main endpoint of this substudy was change in amyloidβ plaque burden from OLE baseline to week 52 and week 104, assessed using florbetapir PET. Florbetapir global
cortical signal was calculated using a prespecified standard uptake value ratio method converted to the Centiloid
scale.
Results: Sixty-seven of the 89 patients initially enrolled had ≥ 1 follow-up scan by August 15, 2018. Mean amyloid
levels were reduced by 39 Centiloids by the first year and 59 Centiloids by year 2, a 3.5-times greater reduction
than was seen after 2 years at 225 mg in SR. At years 1 and 2, 37% and 51% of patients, respectively, had amyloid-β
plaque levels below the amyloid-β positivity threshold.
Conclusion: Results from this exploratory interim analysis of the PET substudy suggest that gantenerumab doses
up to 1200 mg resulted in robust amyloid-β plaque removal at 2 years. PET amyloid levels were consistent with
sparse-to-no neuritic amyloid-β plaques in 51% of patients after 2 years of therapy. Amyloid reductions were similar
to those observed in other placebo-controlled studies that have suggested potential clinical benefit.
Trial registration: ClinicalTrials.gov, NCT01224106 (SCarlet RoAD) and NCT02051608 (Marguerite RoAD).
Keywords: Alzheimer’s disease, Amyloid-β plaque, Centiloid, Disease-modification therapies, Gantenerumab,
Florbetapir, Open-label extension, Positron emission tomography

* Correspondence: gregory.klein@roche.com
1
Roche Pharma Research and Early Development, Basel, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Klein et al. Alzheimer's Research & Therapy

(2019) 11:101

Background
Approximately 50 million people live with dementia
worldwide, and this number is expected to grow to 82
million by 2030 and 152 million by 2050 [1]. Alzheimer’s
disease (AD) is the most common form of dementia, accounting for 60 to 70% of cases; together, AD and other
types of dementia are the fifth leading cause of death
worldwide [2]. Currently, there are no disease-modifying
therapies that can delay disease course, prevent progression, or provide a cure [3]. Available pharmacological
treatments for AD dementia offer mild symptomatic
benefit with no effect on the underlying neuropathology
of the disease [4–10].
AD pathophysiology is characterized by the progressive accumulation of amyloid-β plaques predominantly
comprising amyloid-β peptides around neurons and the
formation of intracellular neurofibrillary tangles containing pathologic tau protein [11]. Deposition of amyloid-β
plaques in the brain parenchyma is likely to occur decades before clinical symptoms manifest [11, 12]. The
extent to which different amyloid-β species contribute to
the pathophysiology of AD remains uncertain [13], although in vitro and ex vivo evidence suggest both soluble oligomers and aggregated plaques are implicated in
neurotoxic effects [13–15]. This hypothesis is being
tested in multiple clinical trials evaluating drugs that can
attenuate the accumulation and/or promote the removal
of amyloid-β in patients with AD [16–19].
Gantenerumab is a fully human anti-amyloid-β IgG1
monoclonal antibody that binds with high affinity to
aggregated amyloid-β species and removes amyloid-β
plaques via Fcγ receptor-mediated microglial phagocytosis
[20–22]. Gantenerumab neutralizes the neurotoxic effect
of oligomeric amyloid-β42 in vivo [22]. The effect of
low-dose subcutaneous (SC) gantenerumab on cognition and function was investigated in 2 global phase 3
studies in patients with prodromal AD (SCarlet RoAD
[SR]; NCT01224106; n = 799) and mild AD (Marguerite
RoAD [MR]; NCT02051608; n = 389) [23, 24]. Dosing
in SR was suspended after interim futility analyses revealed a low likelihood of meeting the primary endpoint at the doses studied (105 and 225 mg SC every 4
weeks [q4w]). Recruitment for MR was subsequently
stopped, although dosing continued. Overall, data
gathered during the double-blind phase of SR suggest
that doses studied were safe and well tolerated [23]. A
dose-dependent decrease in brain amyloid-β plaque
burden was observed by week 100 (measured by positron emission tomography [PET]). Furthermore, dosedependent downstream pharmacodynamic effects were
observed, including reductions in the cerebrospinal
fluid biomarkers phosphorylated tau, total tau, and
neurogranin [23]. A post hoc subgroup analysis of
patients determined to be fast progressors in SR
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(according to Functional Assessment Questionnaire results, normalized hippocampal volume, and Clinical
Dementia Rating Scale Sum of Boxes [CDR-SB] score
at baseline [25]) also suggested a dose-dependent
slowing of decline in the Alzheimer’s Disease Assessment
Scale cognitive subscale (ADAS-Cog) 13, Cambridge
Neuropsychological Test Automated Battery, and MiniMental State Examination (MMSE) after 2 years of
treatment [23, 25].
These observations suggest that higher doses of gantenerumab may have clinically relevant effects on cognition and function in patients with AD, especially in the
early stages of the disease [23]. Accordingly, open-label
extension (OLE) phases incorporating PET substudies
were initiated for SR and MR to assess the short- and
long-term safety and pharmacodynamic effect of gantenerumab SC q4w uptitrated to a maximum dose of
1200 mg. Interim results of the ongoing, exploratory
OLE PET substudies are reported here.

Methods
Study design

Complete study design and methodologic details of the
MR and SR studies have been described elsewhere [23,
24]. Patients aged 50 to 90 years with a clinical diagnosis
of probable prodromal or mild AD based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria and a positive visual amyloid PET assessment from the original double-blind
screening examinations of the MR and SR studies were
eligible to enroll. Patients in SR who received doubleblind treatment and had ≥ 1 follow-up visit and patients
who were currently enrolled in MR were eligible for
OLE participation. All patients entering the OLE at centers already involved in the SR and MR PET substudies
of brain amyloid-β imaging were eligible for the OLE
PET substudy.
All SR and MR patients (including those previously on
placebo) received subcutaneous gantenerumab in the
OLE, which was uptitrated to a maximum dose of 1200
mg each month (Additional file 3: Figure S1). The dosetitration scheme used was based on patients’ apolipoprotein E (APOE) genotype (APOEε4 carrier vs non-carrier)
and the last double-blind treatment dose (gantenerumab
225 mg, gantenerumab 105 mg, or placebo). Gradual
uptitration schemes were used to reach the target dose
of 1200 mg while decreasing the risk of adverse events,
particularly amyloid-related imaging abnormalities
(ARIA) representative of vasogenic edema (ARIA-E).
The target dose was reached within 6 to 10 months in
SR OLE patients and 2 to 6 months in MR OLE patients.
The work described was carried out in accordance
with the Declaration of Helsinki. Written informed
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consent was provided by patients as deemed applicable
by institutional review boards and/or independent ethics
committees.
Patient subgrouping and data cutoff

At the start of the OLE studies, there were considerable
differences between SR and MR patients with respect to
prior exposure and stage of AD. Therefore, for the purposes of this analysis, patients were divided into three
groups. Patients in MR were divided into those who received active drug during the double-blind phase (MR
double-blind active [MR-DBA]) and those who received
placebo (MR double-blind placebo [MR-DBP]), while patients in SR were pooled together in a single group, regardless of assigned treatment in the double-blind phase,
as they were all off treatment for 16 to 19 months prior
to OLE higher dosing. The analyses presented here are
based on a clinical data date of August 15, 2018.
Safety and clinical treatment response monitoring

Patients were monitored by one external independent
monitoring committee until most patients reached the
target dose, after which monitoring was continued by an
internal monitoring committee. Disease severity and
cognitive measures included the MMSE, CDR-SB, and
ADAS-Cog 11. Safety was evaluated by adverse event
reporting, blood safety testing, vital sign assessments,
physical and neurological examinations, electrocardiography, and brain magnetic resonance imaging (MRI).
Prior gantenerumab studies have shown that the most
common safety-related events were ARIA and injectionsite erythema [23]. Interim safety results for the full SR
and MR OLE populations have been reported separately
and indicate that no new safety signals were identified
compared with lower dosing levels [24, 26]. This work
will report relations found between amyloid PET data
and both ARIA and clinical treatment response in patients included in the PET substudy.
Amyloid-β plaque PET imaging

Amyloid PET scans were scheduled at baseline (defined
as prior to OLE day 1 dosing), week 52, and week 104 of
OLE treatment. To minimize patient burden, a new OLE
baseline PET scan was not required if the patient had received one during the double-blind phase within 9 to 12
months prior to OLE dosing. Therefore, for many patients, the duration between OLE baseline and week 52
is considerably longer than 52 weeks.
All PET data were obtained using a target dose of 370
(± 10%) Becquerel (MBq) 18F-florbetapir injected intravenously. A 15-min scan was obtained starting at 50 min
after 18F-florbetapir injection. PET data were checked
for quality and uniformly preprocessed; a global cortical
signal was then calculated using a prespecified standard
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uptake value ratio (SUVR) method identical to the
method reported for analysis in the SR double-blind
study [21]. Briefly, that method computed the volumeweighted, gray matter-masked SUVR of six bilateral cortical regions from the Automated Anatomical Labelling
(AAL) template, normalized by a cerebellar cortex reference region [27, 28]. The original screening 3D T1weighted MRI was segmented in the subject’s space,
then aligned to the AAL template space to perform the
gray-matter masking.
To gain further insight and to allow better comparison
of results from other studies, SUVR values were converted
to Centiloid values. The Centiloid framework has the useful property of rescaling SUVR values obtained via different reference regions, methodologies, or even tracers to a
common scale anchored by Centiloid values of 0 and 100,
which correspond to the transformed SUVR mean values
of a young control group and AD group, respectively [29].
Briefly, paired florbetapir/PiB scans were downloaded
from the GAAIN website (http://www.gaain.org/centiloidproject). SUVRs were calculated using the standard
method from Klunk et al. [29] and the AAL template/gray
matter-masked method used in this work. The Klunk
SUVR method on level 1 11C-Pib data (45 AD patients, 34
young control subjects) was replicated via a regression
analysis with slope 0.994 and R2 = 0.99. A subsequent regression analysis of the level 2 paired florbetapir/11C-PiB
allowed calculation of a single linear regression equation
relating florbetapir AAL SUVR to Centiloid values. The
linear transformations for this prespecified SUVR method
are FBPSUVR = 0.514 × PiBSUVR + 0.749, R2 = 0.75; Centiloid = FBPSUVR × 184.12 − 233.72 [29, 30], where FBPSUVR
and PiBSUVR represent the AAL-calculated SUVR for florbetapir, and PiBSUVR represents the Klunk SUVR method
results for PiB, respectively.
Another important anchor for interpreting PET results is
the threshold for amyloid positivity, which is the quantitative threshold that best discriminates pathologically verified
absence of plaques or sparse plaques from moderate to frequent plaques. Navitsky et al. showed that a Centiloid value
of 24 corresponds to the amyloid positivity threshold for
florbetapir [30]. Independently, the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) PET core laboratory has
established a positivity threshold of 1.11 by using a FreeSurfer method, whole cerebellum reference, and a corresponding Centiloid value of 24 [31]. Using the florbetapir data
available on the GAAIN website (13 young controls, 33 elderly subjects) and calculating SUVR using both the ADNI
FreeSurfer and AAL SUVR processing pipelines, it is found
that the 1.11 ADNI positivity threshold corresponds to a
1.40 value using the AAL method with a cerebellar cortex
reference (Additional file 4: Figure S2) [32]. Transformed
into Centiloids, the 1.40 SUVR also corresponds to a 24Centiloid threshold.
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Statistical analysis

The analysis population included all study participants
receiving ≥ 1 OLE follow-up scan. All analyses presented here are exploratory in nature. Descriptive statistics were used to characterize patient demographics
as well as change from baseline in PET Centiloid
value and CDR-SB, ADAS-Cog 11, and MMSE scores.
PET Centiloid value was also analyzed using a mixed
model for repeated measures (MMRM), with visit,
treatment group, and the interaction for treatment
group by visit as independent variables. An unstructured covariance matrix was used to capture withinpatient correlation. For descriptive group comparisons, the MMRM model was also applied to change
from baseline in the clinical endpoint, with baseline
value, group, and group-by-visit interaction as independent variables. Joint linear mixed effects (JLME)
models were used to evaluate the association between
the annual rate of change in PET and that in CDRSB, ADAS-Cog 11, and MMSE scores while simultaneously controlling the impact of the PET baseline on
the rate of change in the latter. For the ease of model
convergence, PET, CDR-SB, ADAS-Cog 11, and
MMSE scores were standardized to z-scores using the
baseline mean and SD.

Results
Patients

A total of 379 patients were dosed in the SR and MR
OLE trials; of these, 67 had scans at OLE week 52
and 39 had scans at OLE week 104 as of August 15,
2018 (Additional file 3: Figure S1). Patient characteristics at OLE baseline are summarized for OLE week
52 completers in Table 1. Amyloid loads at OLE
baseline were 91, 80, and 50 Centiloids in the MRDBP, MR-DBA, and SR groups, respectively (Table 1).
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Mean (SD) MMSE scores were 21.6 (4.5), 19.3 (5.0),
and 18.8 (4.8), respectively, and ranged from 11 to
29. This indicates that although the original patient
populations in the double-blind studies were prodromal/mild, some patients' health had declined by
the time of OLE baseline, resulting in an overall
mild/moderate patient population for this analysis. All
OLE baseline characteristics of week 52 completers
were broadly consistent with those of week 104 completers, except for mean baseline Centiloid value in
the SR cohort, which was 70 in week 104 completers
(not shown) but only 50 in week 52 completers.
Gantenerumab markedly reduced brain amyloid-β plaque
levels

The reduction in amyloid PET was significant in all
subgroups and at all time points. Mean (SE) PET
Centiloid reductions from baseline were − 42 (7.1), − 48
(8.0), and − 21 (8.3) at week 52 and − 71 (7.7), − 61 (8.9),
and − 34 (8.9) at week 104 in the MR-DBP, MR-DBA, and
SR groups, respectively (Fig. 1); consistent results were
observed for week 104 completers (Additional file 1:
Table S1). Example images from five patients are
shown in Fig. 2. Individually, all week 104 completers
had reduced amyloid, with reductions ranging from
11 to 169 Centiloids, and 51% of patients had amyloid
levels below the positivity threshold at week 104
(Fig. 1b). A strong correlation was seen between
higher amyloid load at OLE baseline and greater
amyloid reduction during the first year of gantenerumab
treatment (Additional file 5: Figure S3). Large regional
reductions were seen throughout the brain regions
primarily involved in AD, with the greatest reductions
observed in the anterior cingulate (Additional file 6:
Figure S4). There were no observed effects of APOE
status on PET reduction.

Table 1 OLE baseline characteristics of patients with PET scan at OLE week 52
Characteristic

MR-DBP (n = 27)

MR-DBA (n = 21)

SR (n = 19)

Age at start of OLE, median (IQR), years

74 (69–77)

65 (59–79)

72 (70–78)

Female, n (%)

12 (44)

11 (52)

11 (58)

White, n (%)

27 (100)

20 (95)

19 (100)

0

9 (33)

10 (48)

2 (11)

1

13 (48)

4 (19)

14 (74)

APOEε4 genotype, n (%)

2
MMSE score at OLE baseline, mean (SD)

5 (19)

7 (33)

3 (16)

21.6 (4.5)

19.3 (5.0)

18.8 (4.8)

Centiloid at OLE baseline, mean (SD)

91.1 (46.8)

79.6 (51.6)

49.6 (52.8)

Duration on high dose, median (IQR), weeksa

35 (33–37)

42 (40–45)

25 (21–33)

Duration between baseline and week 52 PET scan, median (IQR), weeks

68 (60–82)

73 (64–88)

55 (54–58)

Patients with baseline PET scan below amyloid-β threshold, n (%)

0

3 (14)

7 (37)

High dose: ≥ 6 doses (6 months) of 900 to 1200 mg gantenerumab

a
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Fig. 1 Marked and consistent reduction of amyloid load in patients receiving high-dose gantenerumab. a Marked reduction of amyloid-β plaques
in patients receiving high-dose gantenerumab, and consistent reduction of amyloid-β plaques in all patient groups. b Reduction of amyloid-β
plaque burden to below positivity threshold following high-dose gantenerumab. aAnalyzed using a mixed model for repeated measures

Fig. 2 Amyloid-β plaque reduction with gantenerumab. Axial florbetapir brain PET images from five patients displaying reduction of amyloid-β
plaques from OLE baseline to OLE week 52 and OLE week 104. Axial slices are at the level of the basal ganglia. PET images were obtained 50 min
post-injection, SUVR data with the cerebellar cortex as the reference region

Klein et al. Alzheimer's Research & Therapy

(2019) 11:101

Amyloid reduction and ARIA

In our analysis population of OLE PET week 52
substudy completers, 28 patients experienced ARIA-E,
including 7 who reported symptoms. Global amyloid
load at OLE baseline was not significantly different
between the ARIA-E and non-ARIA-E groups
(Table 2), and there were no significant differences
between the ARIA-E and non-ARIA-E groups at
either week 52 or 104; however, a directional trend
toward slightly higher reductions in the ARIA-E
group was observed (Table 2).
Amyloid reduction and clinical results

This open-label, non-placebo-controlled trial was not
designed to support analyses of clinical efficacy. However, exploratory analyses of clinical endpoints were
performed. Baseline and follow-up CDR-SB, ADASCog 11, and MMSE values are summarized in Table 3.
Correlation analysis of change from baseline to week
104 among completers (patients with non-missing
OLE week 104 PET data) suggested a directional
trend for slower clinical decline with higher amyloid
removal for all three endpoints (Fig. 3a, d, g).
“Higher” and “lower” PET amyloid reduction groups
were defined based on the median PET Centiloid
change from baseline to week 52 (Fig. 3c, f, i; median
change threshold, − 34.99 Centiloids) or week 104
(Fig. 3b, e, h; median change threshold, − 55.23 Centiloids), among completers. The “higher” versus “lower”
dichotomization was performed at two different time
points to test the hypothesis that clinical benefit may
follow amyloid reduction temporally [33]; in other
words, higher amyloid reduction at week 52 may be
associated with greater slowing of clinical decline at
week 104, whereas this effect may be less pronounced
when the time point for dichotomization of amyloid
reduction and the clinical evaluation are contemporaneous. At week 104, point estimates for CDR-SB,
ADAS-Cog 11, and MMSE showed numerically less
decline in the higher vs lower PET amyloid reduction
groups, defined at either OLE week 52 or 104. The
differences between the higher and lower PET groups
were non-significant with respect to change from
baseline on all three clinical endpoints. When pooled
together, results from the JLME analysis indicated a
directional but not significant association between the
annual reduction in PET and the annual change in
CDR-SB, ADAS-Cog 11, and MMSE. For instance, an
annual reduction of 0.54 SD in standardized z-score
PET Centiloid would lead to a slowing of 0.55 SD in
the standardized z-score ADAS-Cog increase. However, with the limited sample size and absence of a
placebo arm, robust interpretation and conclusion
from any such analysis is not possible.
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Discussion
This PET substudy of the MR and SR OLE studies investigated the effect of higher-dose gantenerumab on
amyloid-β plaques over 104 weeks in patients with prodromal to moderate AD dementia. Reductions in PET
values to below the amyloid-β positivity threshold were
achieved in 37% of patients at week 52 and 51% at week
104, suggesting that amyloid-β plaques can be reduced
to levels that would not support a neuropathological
diagnosis of AD [34]. In addition, amyloid reductions
were consistently observed across most patients, indicating that gantenerumab has the potential to reduce
amyloid-β plaques as suggested by its proposed mechanism of action of preferential binding to amyloid-β aggregates and consequent plaque removal.
Compared with the PET mean (SD) change observed
with the 225-mg dose during the SR 2-year double-blind
period (− 0.09 [0.14] SUVR, − 16.6 [25.8] Centiloids)
[23], reductions in this OLE substudy were markedly
higher, with an overall reduction in all three cohorts at
week 104 of 59.0 (35.3) Centiloids. The 64.8%, 77.3%,
and 78.2% amyloid reductions in the SR, MR-P, and
MR-NP groups, respectively, were well beyond the
2.4% ± 1.41% test-retest data reported for florbetapir
[35]. Since patients in all three OLE cohorts achieved reductions in amyloid load at week 104 to near or below
the positivity threshold, the lower mean reductions in
the MR-DBA and SR groups compared with the MRDBP group were most likely due to their lower baseline
amyloid loads and not due to a difference in treatment
effect among the three groups. The lower comparative
reduction in the SR group at week 52 could also be explained by the shorter time on high dose compared with
the MR-DBA and MR-DBP groups. Regional analyses indicate that amyloid reductions are fairly uniform
throughout the regions of the brain known to have
amyloid, indicating that sufficient blood-brain barrier
penetration of gantenerumab has occurred to effect
globally large amyloid reductions. Regarding PET
amyloid reductions and ARIA-E, it was observed that
while patients with ARIA-E may have a trend toward
slightly higher amyloid reductions compared with patients without ARIA-E, both groups achieved very large
amyloid reductions. Consequently, the gantenerumab
data indicate that ARIA-E is not a prerequisite for large
amyloid reductions. This result contrasts the data
reported for bapineuzumab, in which there was a lack of
change from baseline in the non-ARIA-E groups [36].
Although comparison of PET amyloid reductions with
gantenerumab vs the effect seen with other anti-amyloid
therapies is challenging [37], use of the Centiloid scale
helps to better understand the current landscape of
therapies with amyloid removal as a mechanism of
action [29, 38]. To date, three other compounds have

n = 11 in SR and total n = 38 at OLE week 104
b
n = 7 in SR and total n = 25 at OLE week 104

a

NA

NA

Change from baseline, mean (SD)

OLE week 52 change from baseline, mean (SD)

− 42.35 (21.23)

46.93 (45.38)
− 44.72 (38.26)

Value at visit, mean (SD)
b

44.30 (45.29)

91.65 (58.77)

86.65 (53.87)

MR-DBA (n = 13)

NA

Baseline value, mean (SD)

Centiloid composite ROI—mean cerebellum gray

MR-DBP (n = 14)

NA

OLE week 52 change from baseline, mean (SD)

Patients without an ARIA-E event

11.16 (38.04)
− 56.85 (29.52)

51.38 (23.42)
− 39.09 (30.90)

Change from baseline, mean (SD)

68.01 (48.78)

MR-DBA (n = 8)

Value at visit, mean (SD)

90.47 (31.67)

MR-DBP (n = 13)

OLE week 52

Baseline value, mean (SD)

Centiloid composite ROI—mean cerebellum gray

Patients with ≥ 1 ARIA-E event

NA

− 6.45 (53.14)

32.95 (42.31)

39.39 (58.71)

SR (n = 12)

NA

− 44.98 (33.43)

22.21 (28.82)

67.19 (38.31)

SR (n = 7)

NA

− 32.15 (41.99)

41.75 (43.67)

73.90 (60.36)

Total (n = 39)

NA

− 45.64 (30.93)

32.60 (33.73)

78.23 (39.03)

Total (n = 28)

− 63.06 (32.84)
− 46.72 (20.26)

− 41.80 (38.85)

18.53 (40.38)

81.59 (66.35)
− 71.81 (48.25)

25.34 (31.63)

97.15 (68.72)

MR-DBA (n = 8)

− 47.26 (12.93)

− 32.53 (31.50)
MR-DBP (n = 10)

− 52.17 (28.66)

11.77 (50.63)

63.94 (41.02)

MR-DBA (n = 3)

− 64.13 (20.28)

18.22 (21.77)

82.35 (33.94)

MR-DBP (n = 6)

OLE week 104

Table 2 Mean change in PET Centiloids from OLE baseline to OLE week 52 and OLE week 104 in patients with and without ≥ 1 ARIA-E event

− 18.68 (16.79)

− 30.38 (17.33)

34.64 (34.31)

65.02 (42.53)

SR (n = 8)

− 55.24 (40.53)

− 73.65 (33.89)

5.18 (24.58)

78.83 (40.21)

SR (n = 4)

− 36.90 (29.92)

− 56.37 (39.37)

26.10 (34.47)

82.47 (60.19)

Total (n = 26)

− 42.91 (31.01)

− 64.30 (25.72)

12.72 (28.46)

77.02 (34.97)

Total (n = 13)
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Change from baseline, mean (SD)

OLE week 52 change from baseline, mean (SD)a

NA

Change from baseline, mean (SD)

a

OLE week 52 change from baseline, mean (SD)b

n = 12 in SR and total n = 37 at OLE week 104
b
n = 14 in MR-DBP and total n = 36 at OLE week 104

7.38 (3.02)
2.08 (2.37)

Value at visit, mean (SD)

5.04 (2.16)

Baseline value, mean (SD)

MR-DBP (n = 24)

4.28 (7.87)
NA

Value at visit, mean (SD)

CDR-SB score

20.22 (8.21)
24.39 (9.94)

Baseline value, mean (SD)

NA

2.55 (2.05)

7.50 (4.21)

5.14 (2.49)

MR-DBA (n = 19)

NA

5.82 (6.44)

28.72 (14.43)

22.92 (10.83)

MR-DBA (n = 19)

NA

NA
MR-DBP (n = 24)

OLE week 52 change from baseline, mean (SD)

ADAS-Cog 11 score

15.80 (5.99)
− 3.45 (3.63)

18.36 (5.08)
− 3.16 (2.81)

Change from baseline, mean (SD)

19.29 (5.03)

MR-DBA (n = 21)

Value at visit, mean (SD)

21.56 (4.52)

MR-DBP (n = 25)

OLE week 52

Baseline value, mean (SD)

MMSE total score

NA

1.58 (1.73)

7.42 (2.84)

5.84 (1.72)

SR (n = 19)

NA

6.74 (8.38)

29.61 (12.06)

22.88 (7.92)

SR (n = 19)

NA

− 1.95 (3.34)

16.89 (6.60)

18.84 (4.83)

SR (n = 19)

Table 3 Mean change in clinical endpoints from OLE baseline to OLE week 52 and OLE week 104

NA

2.07 (2.10)

7.43 (3.32)

5.30 (2.15)

Total (n = 62)

NA

5.51 (7.58)

27.32 (12.14)

21.82 (9.00)

Total (n = 62)

NA

− 2.89 (3.25)

17.13 (5.85)

20.07 (4.86)

Total (n = 64)

− 4.73 (3.82)

20.88 (10.20)

1.39 (1.53)

2.78 (2.85)

7.06 (3.73)

4.28 (1.75)

MR-DBP (n = 16)

1.67 (7.09)

8.17 (13.21)

28.48 (15.49)

1.55 (1.74)

3.55 (3.90)

7.91 (5.75)

4.36 (2.18)

MR-DBA (n = 11)

6.67 (7.78)

11.85 (10.20)

31.03 (16.61)

19.18 (10.03)

MR-DBA (n = 11)

− 2.93 (2.52)
MR-DBP (n = 14)

− 6.18 (5.34)

15.36 (7.26)

21.55 (4.18)

MR-DBA (n = 11)

− 5.20 (4.39)

17.20 (7.16)

22.31 (5.03)

MR-DBP (n = 15)

OLE week 104
SR (n = 12)

2.00 (1.72)

3.04 (2.89)

8.29 (4.29)

5.25 (2.37)

SR (n = 12)

6.19 (9.27)

7.87 (8.28)

26.63 (8.98)

21.50 (9.21)

SR (n = 10)

− 2.25 (3.62)

− 4.58 (5.26)

15.00 (8.26)

19.58 (4.76)

Total (n = 38)

1.64 (1.63)

3.08 (3.12)

7.68 (4.45)

4.60 (2.07)

Total (n = 39)

4.62 (8.17)

9.24 (10.89)

28.75 (14.04)

20.59 (9.64)

Total (n = 35)

− 3.24 (3.36)

− 5.29 (4.87)

15.97 (7.41)

21.26 (4.74)
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Fig. 3 Association of PET and clinical results. a, d, g Regression analysis of CDR-SB, ADAS-Cog 11, and MMSE, respectively, shows directional
slowing of clinical decline with increasing amyloid reduction. b, e, h Change in CDR-SB, ADAS-Cog 11, and MMSE for week 104 completers
stratified by patients with high and low amyloid reduction at week 104 also shows directional slowing of clinical decline in the group with higher
amyloid reduction. c, f, i Stratification of patients by amyloid reduction at the earlier week 52 time point shows increased clinical benefit in the
high PET reduction group, suggesting a temporal lag between amyloid reduction and clinical benefit

reported similar levels of amyloid reduction. The 10-mg/
kg arm of the aducanumab PRIME phase 1b study had a
baseline Centiloid value of 96 (SUVR, 1.44) and a reduction of 71 Centiloids at week 110 [33, 39]. The highestdose group for BAN2401 had a 70-Centiloid reduction at
18 months from 74.5 Centiloids at baseline [40], while the
LY3002813 highest-dose group showed a 68.8-Centiloid
reduction from 111 Centiloids at baseline by week 24 [41].
The most representative gantenerumab OLE cohort for
comparison is the previously untreated MR-DBP arm,
which had a baseline load of 92 Centiloids and a reduction
of 69 Centiloids by week 104. When comparing Centiloid

reductions seen here to those in other studies, it is important to note that the rate of reduction appears to be related
to baseline levels of amyloid as well as to drug effects.
Earlier anti-amyloid-β studies, including bapineuzumab
and solanezumab, as well as BACE-1 studies, such as verubecestat, did not report amyloid values using Centiloid
values, but all three of these showed no or modest amyloidβ reductions, < 5% with respect to baseline after treatment
[42–44]. Other studies have reported amyloid decline in
placebo groups [45], but the magnitude was far smaller
than the amyloid reductions seen with the four high
amyloid-removing monoclonal antibodies listed above.
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There are several limitations to these analyses. The
OLE studies reported here did not have any disease
severity-related inclusion or exclusion criteria, and by
the start of the OLE, some patients had progressed to a
mild-moderate stage. The studies were neither randomized nor blinded and did not include a placebo arm; furthermore, the studies are still ongoing, with additional
subjects expected to reach week 104. In addition, several
measures could be considered to improve the robustness
of the results. Results reported here are from static PET
imaging, which may not account for certain drug effects
(e.g., changes in blood flow or clearance). Dynamic imaging may produce slightly more robust results; however,
the differences due to perfusion changes are likely to be
small compared with the SUVR change seen here [46–
48]. Our use of static PET is consistent with all
previously reported findings on amyloid reduction with
investigational AD therapies [33, 40, 43, 49, 50]. Brain
atrophy progresses over time in AD, potentially even
after amyloid aggregates are removed, and application of
a partial volume correction (PVC) may be useful for
interpreting our findings. PVC will be considered for
future exploratory analysis. It should be noted, however,
that evidence supporting PVC is mixed, with some
reporting an improved signal [51] whereas others report
greater noise [52, 53]. Furthermore, an analysis of
cerebellar gray, pons, and white matter reference region
SUVs compared to cortical target region SUVs (see Additional file 2: Table S2) shows that the SUVR change is
primarily driven by reductions of signal in the target cortical regions, not the reference regions, and is not likely
driven by spillover of cortical white matter activity.
A key step is to clarify how amyloid reductions, such as
those reported here, correspond to any clinical benefit
among patients with early symptomatic AD. Other randomized, parallel-group studies with aducanumab [39] and
BAN2401 [40] have demonstrated PET amyloid signal reduction accompanied by indications of clinical efficacy in a
similar patient population. In addition, a post hoc analysis
of the SR trial demonstrated evidence of gantenerumab
dose-dependent slowing of decline in some clinical efficacy
scales [23]. Whereas two phase III studies of aducanumab
were discontinued due to a low likelihood of reaching the
primary endpoint [54], initially calling into question the relationship of amyloid reduction to clinical benefit, a subsequent analysis of the same studies reported evidence of an
exposure-dependent clinical benefit associated with amyloid
reduction [55]. (Full data from these phase III studies have
not yet been published at the time of this writing.)
In this study, exploratory results showed a directional
trend, whereby patients with higher PET amyloid reduction exhibited numerically less cognitive decline. Considering the limited sample size, heterogeneity among
patients, and other potential confounders, including the

Page 10 of 12

observed relationship between baseline amyloid levels
and amyloid reduction, caution must be used in the interpretation of clinical outcome data, particularly the
comparison to previously published results. Nevertheless, these data do contribute to an overall body of evidence in the field that amyloid reduction is associated
with clinical benefit among patients with early symptomatic AD, as outlined above. The hypothesis that higherdose gantenerumab treatment contributes to clinical
benefit in association with amyloid reduction is currently
being tested in the ongoing GRADUATE phase III pivotal studies (NCT03444870, NCT03443973).

Conclusions
We have shown that gantenerumab reduces amyloid-β
plaques, one of the main pathological hallmarks of
AD. These data and the favorable safety profile observed at these dose levels provide the rationale for
further investigation of the clinical efficacy of gantenerumab, and two pivotal phase III trials in patients
with early AD (GRADUATE 1 and 2) are currently
ongoing [56, 57].
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13195-019-0559-z.
Additional file 1: Table S1. Reduction in Amyloid Load in Patients
Receiving High-Dose Gantenerumab (Week 104 Completers). Findings in
Week 104 completers show continued reduction in amyloid load across
groups over 104 weeks, consistent with the overall group.
Additional file 2: Table S2. SUV Values for Week 104 Completers.
Evaluation of cerebellar gray, pons, and white matter reference region
SUVs compared with cortical target region SUVs show that SUVR change
is primarily driven by changes in the target cortical regions.
Additional file 3: Figure S1. Study Design With Dosing Schedule and
Patient Disposition. (A) Schematic representation of the MR and SR OLE
study designs and dose-titration schedules. All patients in the OLE (including
those previously on placebo) received gantenerumab subcutaneously every
4 weeks. Dose-titration schedules for uptitration to 1200 mg were assigned
based on APOEε4 carrier status and last treatment dose during the doubleblind phase. (B) Patient disposition. a Including 1 patient who missed their
week 52 visit.
Additional file 4: Figure S2. Linear Regression of AAL SUVR (cerebellar
gray reference) vs ADNI FreeSurfer (whole cerebellum reference). Linear
regression of SUVR results computed on the same ADNI patients allows
transformation of the previously published 1.11 amyloid-β positivity
threshold to a value of 1.40 for the method here using a cerebellar cortex
reference region. The 95% CIs (shaded area) were calculated using the
bootstrap (quartile) method.
Additional file 5: Figure S3. Correlation Between Amyloid Load at OLE
Baseline and Amyloid Change Over Time. Rate of amyloid reduction
during the first year of gantenerumab treatment appears to be linked to
baseline amyloid burden. Higher rates of amyloid reduction are seen with
greater baseline burden.
Additional file 6: Figure S4. Regional Reductions in Amyloid Load.
Amyloid reductions are seen in all regions known to be involved with
amyloid pathology. Highest reductions are seen in the cingulate, frontal,
and striatum areas. When adjusted for baseline amyloid burden, the
caudate region shows the greatest regional reduction.
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